Immune cells in the intestine may reduce neuroimflammation in multiple sclerosis (MS) patients, a pre-clinical study suggests.
Moreover, the augmented number of these cells was sufficient to suppress brain inflammation in an MS mouse model.
The findings were reported in the study “Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10,” published in the journal Cell.
“If we can understand what these cells are reacting to, we can potentially treat MS by modulating our gut commensals,” Jennifer Gommerman, PhD, senior author of the study said in a press release, referring to the bacteria that live in the gut. Gommerman is a professor of immunology at the University of Toronto, Canada.
“That might be easier than getting drugs into the brain, which is a strategy that hasn’t always worked in MS,” Gommerman added.
MS is a chronic inflammatory disease characterized by the loss of myelin — the fat-rich substance that protects nerve fibers (axons) — leading to the progressive destruction of nerve cells. The disease is triggered by the malfunction of the immune system, including immune B- and T-cells.
Now, researchers at the University of Toronto and UC San Francisco (UCSF) in California explained how recent divergent results from clinical trials targeting B-cells prompted the team to further investigate their role during neuroinflammation.
“We already knew what was and was not working in the clinic,” said Gommerman. “But here we’ve uncovered the molecular and cellular mechanism at play. It’s a kind of reverse translation approach, which highlights the importance of the gut-brain axis in MS and other autoimmune conditions.”
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?